Dysregulation of the Sirt5/IDH2 axis contributes to sunitinib resistance in human renal cancer cells

Dysregulation of the Sirt5/IDH2 axis contributes to sunitinib resistance in human renal cancer cells

Sunitinib (Sun), a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, is the standard first‐line treatment against advanced clear cell renal cell carcinoma (RCC), but resistance to therapy is inevitable. Reactive oxygen species production is associated with sensitivity to chem...

Full description

Bibliographic Details
Main Authors:	Liang Meng, Deqiang Chen, Gaopei Meng, Li Lu, Chenggang Han
Format:	Article
Language:	English
Published:	Wiley 2021-03-01
Series:	FEBS Open Bio
Subjects:	clear cell renal cell carcinoma desuccinylation isocitrate dehydrogenase 2 Sirt5 sunitinib
Online Access:	https://doi.org/10.1002/2211-5463.13090

Similar Items

SIRT5 functions as a tumor suppressor in renal cell carcinoma by reversing the Warburg effect
by: Liu Yihan, et al.
Published: (2021-12-01)

SIRT5 promote malignant advancement of chordoma by regulating the desuccinylation of c-myc
by: Minghui Jiang, et al.
Published: (2024-03-01)

Emerging Roles of SIRT5 in Metabolism, Cancer, and SARS-CoV-2 Infection
by: Emanuele Fabbrizi, et al.
Published: (2023-03-01)

Ιmpact of sunitinib-induced hypothyroidism on survival of patients with metastatic renal cancer
by: Theofanis Vasileiadis, et al.
Published: (2019-04-01)

Sunitinib resistance in renal cell carcinoma
by: Christudas Morais
Published: (2014-04-01)

Molecular and Functional Analysis of Sunitinib-Resistance Induction in Human Renal Cell Carcinoma Cells
by: Magdalena Rausch, et al.
Published: (2021-06-01)

PFKFB4 is overexpressed in clear-cell renal cell carcinoma promoting pentose phosphate pathway that mediates Sunitinib resistance
by: Chenchen Feng, et al.
Published: (2021-09-01)

Acute Acalculous Cholecystitis Associated with Sunitinib Treatment for Renal Cell Carcinoma
by: Se Woong Choi, et al.
Published: (2020-02-01)

Metabolomic Analysis to Elucidate Mechanisms of Sunitinib Resistance in Renal Cell Carcinoma
by: Tomonori Sato, et al.
Published: (2020-12-01)

Low level of isocitrate dehydrogenase 1 predicts unfavorable postoperative outcomes in patients with clear cell renal cell carcinoma
by: Pingcuo Laba, et al.
Published: (2018-08-01)

Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial
by: Jun Guo, et al.
Published: (2018-05-01)

The Impact of Modifying Sunitinib Treatment Scheduling on Renal Cancer Tumor Biology and Resistance
by: Harrison Sicheng Lin, et al.
Published: (2022-01-01)

Activity and safety of sunitinib in poor risk metastatic renal cell carcinoma patients
by: Romualdo Barroso-Sousa, et al.
Published: (2014-12-01)

Expression of IDH1, ATRX, p53 in Diagnosis of Gliomas as Per 2016 WHO Classification
by: Lokesh Kumar, et al.
Published: (2023-07-01)

Complete remission of metastatic renal cell carcinoma to the bone with sunitinib
by: Akihiro Yoshimura, et al.
Published: (2020-09-01)

Key sunitinib‐related biomarkers for renal cell carcinoma
by: Yun Peng, et al.
Published: (2021-10-01)

Metastatic Renal Cell Carcinoma: Sunitinib as First-Line Treatment; Results of a Retrospective Study
by: El-Hadaad Hend Ahmed, et al.
Published: (2015-12-01)

Research progress of IDH1 and IDH2 mutations in gliomas
by: Shan-shan ZHANG, et al.
Published: (2015-11-01)

Clear Cell Renal Cell Carcinoma, Diagnostic and Therapeutic Difficulties, Case Report and Literature Review
by: Weronika Stolpa, et al.
Published: (2022-09-01)

Role of Sam68 in Sunitinib induced renal cell carcinoma apoptosis
by: Zeshen Wu, et al.
Published: (2022-10-01)

Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies
by: Xinan Sheng, et al.
Published: (2020-03-01)

Leukocytoclastic Vasculitis after Long-Term Treatment with Sunitinib: A Case Report
by: Alexandra Karadimou, et al.
Published: (2011-08-01)

Catfish Egg Lectin Enhances the Cytotoxicity of Sunitinib on Gb3-Expressing Renal Cancer Cells
by: Jun Ito, et al.
Published: (2023-08-01)

Co-expression of cancer driver genes: IDH-wildtype glioblastoma-derived tumorspheres
by: Seon-Jin Yoon, et al.
Published: (2020-12-01)

Identification of MX2 as a Novel Prognostic Biomarker for Sunitinib Resistance in Clear Cell Renal Cell Carcinoma
by: Yuang Wei, et al.
Published: (2021-07-01)

Genome-Wide Meta-Analysis Identifies Variants in <i>DSCAM</i> and <i>PDLIM3</i> That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib
by: Meta H. M. Diekstra, et al.
Published: (2022-06-01)

The SIRT7-mediated deacetylation of CHD1L amplifies HIF-2α-dependent signal that drives renal cell carcinoma progression and sunitinib resistance
by: Hongchao He, et al.
Published: (2023-09-01)

Concurrent IDH1 and IDH2 mutations in glioblastoma: A case report
by: Ali S. Haider, et al.
Published: (2023-04-01)

Sunitinib in Metastatic Renal Cell Carcinoma: The Pharmacological Basis of the Alternative 2/1 Schedule
by: Antonello Di Paolo, et al.
Published: (2017-08-01)

Case report of a renal cell carcinoma patient with acute pancreatitis under both sunitinib and axitinib treatment
by: Utku Oflazoglu, et al.
Published: (2016-08-01)

Long Non-coding RNA CCAT1 Acts as an Oncogene and Promotes Sunitinib Resistance in Renal Cell Carcinoma
by: Liping Shan, et al.
Published: (2020-09-01)

Maffucci syndrome complicated by giant chondrosarcoma in the left ankle with an IDH1 R132C mutation: a case report
by: Haiyan Lv, et al.
Published: (2022-06-01)

Study of Surrogate Immunohistochemical Markers IDH1, ATRX, BRAF V600E, and p53 Mutation in Astrocytic and Oligodendroglial Tumors
by: Santosh Sharma, et al.
Published: (2023-08-01)

YTHDC1 is downregulated by the YY1/HDAC2 complex and controls the sensitivity of ccRCC to sunitinib by targeting the ANXA1-MAPK pathway
by: Wei Li, et al.
Published: (2022-08-01)

Corrigendum: Long non-coding RNA CCAT1 acts as an oncogene and promotes sunitinib resistance in renal cell carcinoma
by: Liping Shan, et al.
Published: (2023-08-01)

Sunitinib maleate administration before percutaneous CT-guided cryoablation for large renal cell carcinoma: A case report
by: Kaori Nishizawa, MD, et al.
Published: (2022-12-01)

IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
by: Claudio Cerchione, et al.
Published: (2021-03-01)

Mutant IDH in Gliomas: Role in Cancer and Treatment Options
by: Georgios Solomou, et al.
Published: (2023-05-01)

Metformin Use and the Outcome of Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib
by: Fiala O, et al.
Published: (2021-05-01)

Suppression of SREBP-1 Expression by Simvastatin Decreases Visfatin-Induced Chemoresistance to Sunitinib in Human Renal Carcinoma 786-O Cells
by: Te-Chuan Chen, et al.
Published: (2022-11-01)